Company Filing History:
2 out of 672 
2 out of 1,777 
1 out of 832,880 Years Active: 1998-2001
Title: Jan Moller Mikkelson: Innovator in Protein Complexes
Introduction
Jan Moller Mikkelson is a notable inventor based in Gentofte, Denmark. He has made significant contributions to the field of biotechnology, particularly in the development of recombinant protein complexes. With a total of 3 patents, Mikkelson's work has advanced the understanding and production of essential proteins.
Latest Patents
Mikkelson's latest patents focus on protein complexes having factor VIII:C activity and their production. These recombinant protein complexes are expressed in a eukaryotic host cell by transforming the host cell with first and second expression cassettes. The first cassette encodes a polypeptide substantially homologous to the human Factor VIII:C A domain, while the second encodes a polypeptide substantially homologous to the human Factor VIII:C C domain. Notably, the first polypeptide may be extended at its C-terminal with a human Factor VIII:C B domain N-terminal peptide, a polypeptide spacer of 3-40 amino acids, and a human Factor VIII:C B domain C-terminal peptide. The expression of the second polypeptide is enhanced by employing an α1-antitrypsin signal sequence.
Career Highlights
Throughout his career, Mikkelson has worked with prominent companies in the biotechnology sector. He has been associated with Chiron Corporation and Novo Nordisk A/S, where he contributed to various innovative projects. His expertise in protein engineering has positioned him as a key figure in the development of therapeutic proteins.
Collaborations
Mikkelson has collaborated with esteemed colleagues, including Barbara S. Chapman and Rae Lyn Burke. These partnerships have fostered a collaborative environment that has led to significant advancements in their respective fields.
Conclusion
Jan Moller Mikkelson's contributions to the field of biotechnology, particularly in the area of recombinant protein complexes, have been invaluable. His innovative patents and collaborations highlight his commitment to advancing scientific knowledge and improving therapeutic solutions.